Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine (FAKHRAVAC®) in healthy adults aged 18-55 years: Randomized, double-blind, placebo-controlled, phase I clinical trial.

Autor: Ansarifar A; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Farahani RH; AJA University of Medical Sciences, Tehran, Iran., Rahjerdi AK; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran., Ahi M; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Sheidaei A; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Gohari K; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Rahimi Z; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Gholami F; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Basiri P; Stem Cell Technology Research Center (STRC), Tehran, Iran., Moradi M; Stem Cell Technology Research Center (STRC), Tehran, Iran., Jahangiri A; Stem Cell Technology Research Center (STRC), Tehran, Iran., Naderi K; Stem Cell Technology Research Center (STRC), Tehran, Iran., Ghasemi S; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran., Khatami P; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran., Honari M; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran., Khodaverdloo S; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran., Shooshtari M; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran., Azin HM; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran., Moradi S; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran., Shafaghi B; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran., Allahyari H; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran., Monazah A; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran., Poor AK; Milad Daro Noor Pharmaceutical (MDNP) Company, Tehran, Iran., Bakhshande H; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Taghva Z; Stem Cell Technology Research Center (STRC), Tehran, Iran., Nia MK; Stem Cell Technology Research Center (STRC), Tehran, Iran., Dodaran MS; Clinical Trial Center of Iran University of Medical Sciences, Tehran, Iran., Foroughizadeh M; Malek Ashtar University of Technology, Tehran, Iran.

Publikováno v: Vaccine: X [Vaccine X] 2023 Oct 27; Vol. 15, pp. 100401. Date of Electronic Publication: 2023 Oct 27 (Print Publication: 2023).

COVID-19 and its implications on the clinico-radiological course of multiple sclerosis: A case-control study.

Autor: Rahmani M; Department of Neurology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran., Moghadasi AN; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran., Shahi S; Tehran Heart Center, Cardiovascular Research Center, Tehran University of Medical Science, Tehran, Iran., Eskandarieh S; Multiple Sclerosis Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran., Azizi H; Tehran University of Medical Science, Tehran, Iran., Hasanzadeh A; Tehran University of Medical Science, Tehran, Iran., Ahmadzade A; Tehran University of Medical Science, Tehran, Iran., Dehnavi AZ; Department of Neurology, School of Medicine, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran., Farahani RH; Department of Infectious Diseases, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran., Aminianfar M; Department of Infectious and Tropical Diseases, Be'sat Hospital, AJA University of Medical Sciences, Tehran, Iran., Naeini AR; Department of Neurology, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.

Publikováno v: Medicina clinica (English ed.) [Med Clin (Engl Ed)] 2023 Mar 10; Vol. 160 (5), pp. 187-192. Date of Electronic Publication: 2023 Mar 03.

Evaluation of the efficacy of oral nano-silymarin formulation in hospitalized patients with COVID-19: A double-blind placebo-controlled clinical trial.

Autor: Aryan H; Department of Anesthesiology and Intensive Care, Aja University of Medical Sciences, Tehran, Iran., Farahani RH; Infectious Disease Research Center, AJA University of Medical Sciences, Tehran, Iran., Chamanara M; Toxicology Research Center, Aja University of Medical Sciences, Tehran, Iran.; Department of Pharmacology, School of Medicine, Aja University of Medical Sciences, Tehran, Iran., Elyasi S; Department of Clinical Pharmacy, School of Pharmacy Mashhad University of Medical Sciences, Mashhad, Iran., Jaafari MR; Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.; Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran., Haddad M; Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran., Sani AT; Department of Infectious Diseases and Tropical medicine, Faculty of medicine, Mashhad University of medical sciences, Mashhad, Iran., Ardalan MA; Faculty of Medicine, Mashhad University of Medical Sciences Mashhad, Mashhad, Iran., Mosaed R; Internal Medicine Department, School of Medicine, AJA University of Medical Sciences, Tehran, Iran.

Publikováno v: Phytotherapy research : PTR [Phytother Res] 2022 Oct; Vol. 36 (10), pp. 3924-3931. Date of Electronic Publication: 2022 Jul 20.

The effect of IGF-1 plasma concentration on COVID-19 severity.

Autor: Hazrati E; Department of Anesthesiology and Critical Care, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran., Gholami M; Department of Medical Microbiology, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran; Infectious Diseases Research Center, Aja University of Medical Sciences, Tehran, Iran. Electronic address: Mohammadg19@gmail.com., Farahani RH; Department of Infectious and Tropical Diseases, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran., Ghorban K; Infectious Diseases Research Center, Aja University of Medical Sciences, Tehran, Iran; Department of Medical Immunology, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran., Ghayomzadeh M; Murdoch Applied Sports Science Laboratory, Murdoch University, Perth, Western Australia, Australia. Electronic address: morteza_ghayomzadeh@yahoo.com., Rouzbahani NH; Infectious Diseases Research Center, Aja University of Medical Sciences, Tehran, Iran; Department of Medical Immunology, Faculty of Medicine, Aja University of Medical Sciences, Tehran, Iran. Electronic address: n-hosseini@razi.tums.ac.ir.

Publikováno v: Microbial pathogenesis [Microb Pathog] 2022 Mar; Vol. 164, pp. 105416. Date of Electronic Publication: 2022 Jan 26.

Diagnostic Performance of Chest CT-Scan and First RT-PCR Testing for COVID-19 in Iranian Population.

Autor: Farahani RH; School of Medicine, AJA University of Medical Sciences, Tehran, Iran., Mosallaei M; School of Medicine, AJA University of Medical Sciences, Tehran, Iran., Hazrati E; School of Medicine, AJA University of Medical Sciences, Tehran, Iran., Ehtesham N; Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran., Pakzad B; Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran., Sabet MN; School of Medicine, AJA University of Medical Sciences, Tehran, Iran., Esmaeilzadeh E; School of Medicine, AJA University of Medical Sciences, Tehran, Iran.

Publikováno v: Iranian journal of public health [Iran J Public Health] 2021 Aug; Vol. 50 (8), pp. 1740-1742.